Clinical trial • Not applicable • Immunology|Nephrology

RITUXIMAB for ANCA-associated vasculitis | End-stage renal disease

Not applicable trial of RITUXIMAB for ANCA-associated vasculitis | End-stage renal disease.

Overview

Trial Therapeutic Area
Immunology|Nephrology
Trial Disease
ANCA-associated vasculitis | End-stage renal disease
Trial Stage
Not applicable
Drug Modality
Monoclonal antibody|Small molecule

Key dates

Initial CTIS Submission Date
06-03-2024
First CTIS Authorization Date
09-04-2024

Trial design

Randomised, open-label, comparator (maintenance immunosuppressive therapy) includes: rituximab (injectable solution; maximum reported dose 500 mg), azathioprine (oral; up to 2 mg/kg), prednisone / prednisolone (oral; up to 20 mg), mycophenolate mofetil (oral; up to 2 g). (schedule/frequency not specified in the record.)-controlled Not applicable trial in France.

Randomised
Yes
Open Label
Yes
Comparator
Comparator (maintenance immunosuppressive therapy) includes: RITUXIMAB (injectable solution; maximum reported dose 500 mg), AZATHIOPRINE (oral; up to 2 mg/kg), PREDNISONE / PREDNISOLONE (oral; up to 20 mg), MYCOPHENOLATE MOFETIL (oral; up to 2 g). (Schedule/frequency not specified in the record.)
Target Sample Size
136
Trial Duration For Participant
730

Eligibility

Recruits 136 No vulnerable population was selected. Patients under guardianship or trusteeship are excluded. Inability to understand and sign the informed consent is an exclusion criterion. Participation requires written informed consent from the patient (ICF_adults present); no assent procedures for minors are provided because only adults (≥18) are eligible..

Pregnancy Exclusion
Pregnant women; Women of child-bearing age without effective method of contraception
Vulnerable Population
No vulnerable population was selected. Patients under guardianship or trusteeship are excluded. Inability to understand and sign the informed consent is an exclusion criterion. Participation requires written informed consent from the patient (ICF_adults present); no assent procedures for minors are provided because only adults (≥18) are eligible.

Inclusion criteria

  • {"criterion_text":"- Age ≥ 18 years and ≤ 90 years\n- Patients affected by a GPA or MPA AAV with a renal injury\n- Patients with initial manifestation or relapse of AAV\n- Patients with ESRD, defined by a glomerular filtration rate estimated using the MDRD formula ≤15 mL/min or requirement for dialysis for more than 60 days\n- Patients with ESRD on native kidney\n- Patients who gave written informed consent for participation in the study\n- Patients with affiliation to the French social security system"}

Exclusion criteria

  • {"criterion_text":"- Patients who experienced severe extra-renal disease due to AAV (intra-alveolar haemorrhage with blood oxygen saturation ≤ 85% on room air or ventilated, or central nervous system disease) in the last 12 months prior to inclusion\n- Inability to understand and sign the informed consent\n- Pregnant women\n- Women of child-bearing age without effective method of contraception\n- Age < 18 years or > 90 years\n- Patients under guardianship or trusteeship\n- Patients with AAV-associated renal involvement (with active inflammatory lesions in kidney biopsy) diagnosed less than three months and receiving induction treatment with Cyclophosphamide or Rituximab or diagnosed less than 45 days for patients who have received only treatment based on steroid infusion without Cyclophosphamide or Rituximab\n- Patients who received maintenance immunosuppressive treatment for more than 6 months during the last 12 months\n- Patient with a diagnosis of vasculitis other than GPA or MPA\n- Patients with another immunologic systemic disease (Lupus, sarcoidosis…)\n- Patients with active HCV, HBV or HIV infection\n- Patients with a history of serious viral infection (CMV, HHV8, etc.) in the 2 months prior to the inclusion, or severe uncontrolled chronic infection (tuberculosis, etc.)\n- Patients with uncontrolled cancer or hemopathy\n- Kidney transplant patient"}

Endpoints

Primary endpoints

  • {"endpoint_text":"- The primary end point will be the time between randomization and the first severe prejudicial event (severe infection, major AAV relapse, death) during 24 months of follow-up.","definition_or_measurement_approach":"Severe prejudicial event defined as severe infection, major AAV relapse, or death during 24 months. Major relapses will be defined according to current European recommendations (EULAR). Severe infection is defined as an infection requiring hospital admission."}

Recruitment

Planned Sample Size
136
Recruitment Window Months
157
Consent Approach
Written informed consent is required from participants (ICF_adults and SIS_adults documents present). Only adults (≥18 years) are eligible; inability to understand or sign informed consent is an exclusion. Consent documents provided for adults; primary language indicated by translations and site country is French (French translation entries present). No assent for minors.

Geography

Total Number Of Sites
53
Total Number Of Participants
136

France

Earliest CTIS Part Ii Submission Date
03-04-2024
Latest Decision Or Authorization Date
22-01-2026
Processing Time Days
659
Number Of Sites
53
Number Of Participants
136

Sites

Site Name
Hôpitaux Civils de Colmar
Department Name
Nephrology
Principal Investigator Name
Alexandre KLEIN
Principal Investigator Email
klein.alexandre@ch-colmar.fr
Contact Person Name
Alexandre KLEIN
Contact Person Email
klein.alexandre@ch-colmar.fr
Site Name
Centre Hospitalier Universitaire De Lille
Department Name
Nephrology
Principal Investigator Name
Céline LEBAS
Principal Investigator Email
Celine.LEBAS@chru-lille.fr
Contact Person Name
Céline LEBAS
Contact Person Email
Celine.LEBAS@chru-lille.fr
Site Name
HÔPITAL EUROPÉEN GEORGE POMPIDOU
Department Name
Nephrology
Principal Investigator Name
Alexandre KARRAS
Principal Investigator Email
alexandre.karras@aphp.fr
Contact Person Name
Alexandre KARRAS
Contact Person Email
alexandre.karras@aphp.fr
Site Name
Centre Hospitalier Departemental Vendee
Department Name
Nephrology
Principal Investigator Name
Grégoire COUVRAT-DESVERGNES
Principal Investigator Email
gregoire.couvrat@ght85.fr
Contact Person Name
Grégoire COUVRAT-DESVERGNES
Contact Person Email
gregoire.couvrat@ght85.fr
Site Name
Hopital privée La Louvière
Department Name
Nephrology
Principal Investigator Name
Laurence VRIGNEAUD
Principal Investigator Email
l.vrigneaud@gmail.com
Contact Person Name
Laurence VRIGNEAUD
Contact Person Email
l.vrigneaud@gmail.com
Site Name
Centre Hospitalier Universitaire De Rennes
Department Name
Nephrology
Principal Investigator Name
Elsa VABRET
Principal Investigator Email
elsa.vabret@chu-rennes.fr
Contact Person Name
Elsa VABRET
Contact Person Email
elsa.vabret@chu-rennes.fr
Site Name
Centre Hospitalier Universitaire De Dijon
Department Name
Nephrology
Principal Investigator Name
Mathieu LEGENDRE
Principal Investigator Email
mathieu.legendre@chu-dijon.fr
Contact Person Name
Mathieu LEGENDRE
Contact Person Email
mathieu.legendre@chu-dijon.fr
Site Name
Besancon University Hospital Center
Department Name
Nephrology
Principal Investigator Name
Didier DUCLOUX
Principal Investigator Email
dducloux@chu-besancon.fr
Contact Person Name
Didier DUCLOUX
Contact Person Email
dducloux@chu-besancon.fr
Site Name
Hôpital Bichat Claude-Bernard AP-HP
Department Name
Nephrology
Principal Investigator Name
Eric DAUGAS
Principal Investigator Email
eric.daugas@aphp.fr
Contact Person Name
Eric DAUGAS
Contact Person Email
eric.daugas@aphp.fr
Site Name
Aub Sante
Department Name
Nephrology
Principal Investigator Name
Bruno LEGENDRE
Principal Investigator Email
bruno.legendre@aub-sante.fr
Contact Person Name
Bruno LEGENDRE
Contact Person Email
bruno.legendre@aub-sante.fr
Site Name
Centre Hospitalier Universitaire D'Angers
Department Name
Nephrology
Principal Investigator Name
Jean François AUGUSTO
Principal Investigator Email
JFAugusto@chu-angers.fr
Contact Person Name
Jean François AUGUSTO
Contact Person Email
JFAugusto@chu-angers.fr
Site Name
AUB SANTE
Department Name
Nephrology
Principal Investigator Name
Eric LARUELLE
Principal Investigator Email
eric.laruelle@aub-sante.fr
Contact Person Name
Eric LARUELLE
Contact Person Email
eric.laruelle@aub-sante.fr
Site Name
Centre Hospitalier Universitaire De Saint Etienne
Department Name
Nephrology
Principal Investigator Name
Christophe MARIAT
Principal Investigator Email
christophe.mariat@univ-st-etienne.fr
Contact Person Name
Christophe MARIAT
Site Name
Centre Hospitalier Eure-Seine
Department Name
Nephrology
Principal Investigator Name
Ancuta BOUFFANDEAU
Principal Investigator Email
ancuta.bouffandeau@chi-eureseine.fr
Contact Person Name
Ancuta BOUFFANDEAU
Site Name
Hopital Saint Louis
Department Name
Nephrology
Principal Investigator Name
Evangéline PILLEBOUT
Principal Investigator Email
evangeline.pillebout@aphp.fr
Contact Person Name
Evangéline PILLEBOUT
Contact Person Email
evangeline.pillebout@aphp.fr
Site Name
Centre Hospitalier Le Mans
Department Name
Neph
Principal Investigator Name
Jean Philippe COINDRE
Principal Investigator Email
jpcoindre@ch-lemans.fr
Contact Person Name
Jean Philippe COINDRE
Contact Person Email
jpcoindre@ch-lemans.fr
Site Name
Centre Hospitalier Intercommunal De Cornouaille
Department Name
Nephrology
Principal Investigator Name
Pascale SIOHAN
Principal Investigator Email
p.siohan@ch-cornouaille.fr
Contact Person Name
Pascale SIOHAN
Contact Person Email
p.siohan@ch-cornouaille.fr
Site Name
Centre Hospitalier Groupe Hospitalier De La Rochelle Re Aunis
Department Name
Nephrology
Principal Investigator Name
François POURREAU
Principal Investigator Email
francois.pourreau@ch-larochelle.fr
Contact Person Name
François POURREAU
Site Name
AUB Avranches
Department Name
Nephrology
Principal Investigator Name
Bruno LEGENDRE
Principal Investigator Email
bruno.legendre@aub-sante.fr
Contact Person Name
Bruno LEGENDRE
Contact Person Email
bruno.legendre@aub-sante.fr
Site Name
Centre Hospitalier Angouleme
Department Name
Nephrology
Principal Investigator Name
Dominique BLANCHIER
Principal Investigator Email
dominique.blanchier@ch-angouleme.fr
Contact Person Name
Dominique BLANCHIER
Site Name
Centre Hospitalier Regional Universitaire De Tours
Department Name
Nephrology
Principal Investigator Name
Jean-Michel HALIMI
Principal Investigator Email
jmhalimi@univ-tours.fr
Contact Person Name
Jean-Michel HALIMI
Contact Person Email
jmhalimi@univ-tours.fr
Site Name
Centre Hospitalier D'Arras
Department Name
Nephrology
Principal Investigator Name
Abo Bakr ABD EL FATAH MOHAMED
Contact Person Name
Abo Bakr ABD EL FATAH MOHAMED
Site Name
Les Hopitaux De Chartres
Department Name
Nephrology
Principal Investigator Name
Mohamed Riadh TROUDI
Principal Investigator Email
mtroudi@ch-chartres.fr
Contact Person Name
Mohamed Riadh TROUDI
Contact Person Email
mtroudi@ch-chartres.fr
Site Name
Centre Hospitalier Universitaire De Nimes
Department Name
Nephrology
Principal Investigator Name
Olivier MORRANE
Principal Investigator Email
Olivier.MORANNE@chu-nimes.fr
Contact Person Name
Olivier MORRANE
Contact Person Email
Olivier.MORANNE@chu-nimes.fr
Site Name
Centre Hospitalier Universitaire De Nantes
Department Name
Nephrology
Principal Investigator Name
Clément DELTOMBE
Principal Investigator Email
clement.deltombe@chu-nantes.fr
Contact Person Name
Clément DELTOMBE
Contact Person Email
clement.deltombe@chu-nantes.fr
Site Name
CHU De Rouen
Department Name
Nephrology
Principal Investigator Name
Dominique GUERROT
Principal Investigator Email
dominique.guerrot@chu-rouen.fr
Contact Person Name
Dominique GUERROT
Contact Person Email
dominique.guerrot@chu-rouen.fr
Site Name
APHP Ambroise Paré
Department Name
Nephrology
Principal Investigator Name
Julien DANG
Principal Investigator Email
julien.dang@aphp.fr
Contact Person Name
Julien DANG
Contact Person Email
julien.dang@aphp.fr
Site Name
Centre Hospitalier Universitaire Grenoble Alpes
Department Name
Nephrology
Principal Investigator Name
Pierre-Louis CARRON
Principal Investigator Email
PLCarron@chu-grenoble.fr
Contact Person Name
Pierre-Louis CARRON
Contact Person Email
PLCarron@chu-grenoble.fr
Site Name
Hopital Tenon
Department Name
Nephrology
Principal Investigator Name
Jean-Jacques BOFFA
Principal Investigator Email
jean-jacques.boffa@aphp.fr
Contact Person Name
Jean-Jacques BOFFA
Contact Person Email
jean-jacques.boffa@aphp.fr
Site Name
Centre Hospitalier Lyon Sud
Department Name
Nephrology
Principal Investigator Name
Laëtitia KOPPE
Principal Investigator Email
laetitia.koppe@chu-lyon.fr
Contact Person Name
Laëtitia KOPPE
Contact Person Email
laetitia.koppe@chu-lyon.fr
Site Name
CH Emile Roux
Department Name
Nephrology
Principal Investigator Name
Marc BOUILLER
Principal Investigator Email
marc.bouiller@ch-lepuy.fr
Contact Person Name
Marc BOUILLER
Contact Person Email
marc.bouiller@ch-lepuy.fr
Site Name
Centre Hospitalier Universitaire De Montpellier
Department Name
Nephrology
Principal Investigator Name
Guillaume JEANTET
Principal Investigator Email
g-jeantet@chu-montpellier.fr
Contact Person Name
Guillaume JEANTET
Contact Person Email
g-jeantet@chu-montpellier.fr
Site Name
Groupe Hospitalier De La Region De Mulhouse Et Sud Alsace
Department Name
Nephrology
Principal Investigator Name
François CHANTREL
Principal Investigator Email
CHANTRELF@ghrmsa.fr
Contact Person Name
François CHANTREL
Contact Person Email
CHANTRELF@ghrmsa.fr
Site Name
Centre Hospitalier Universitaire De Toulouse
Department Name
Nephrology
Principal Investigator Name
Dominique CHAUVEAU
Principal Investigator Email
chauveau.d@chu-toulouse.fr
Contact Person Name
Dominique CHAUVEAU
Contact Person Email
chauveau.d@chu-toulouse.fr
Site Name
Centre Hospitalier Regional Et Universitaire De Brest
Department Name
Nephrology
Principal Investigator Name
Catherine HANROTEL-SALIOU
Principal Investigator Email
catherine.hanrotel-saliou@chu-brest.fr
Contact Person Name
Catherine HANROTEL-SALIOU
Site Name
Centre Hospitalier Universitaire Amiens Picardie
Department Name
Nephrology
Principal Investigator Name
Dimitri TITECA-BEAUPORT
Principal Investigator Email
Titeca.Dimitri@chu-amiens.fr
Contact Person Name
Dimitri TITECA-BEAUPORT
Contact Person Email
Titeca.Dimitri@chu-amiens.fr
Site Name
AUB SANTE LORIENT
Department Name
Nephrology
Principal Investigator Name
Gabrielle DUNEAU
Principal Investigator Email
gabrielle.duneau@aub-sante.fr
Contact Person Name
Gabrielle DUNEAU
Contact Person Email
gabrielle.duneau@aub-sante.fr
Site Name
Centre Hospitalier Et Universitaire De Limoges
Department Name
Nephrology
Principal Investigator Name
Marie ESSIG
Principal Investigator Email
marie.essig@unilim.fr
Contact Person Name
Marie ESSIG
Contact Person Email
marie.essig@unilim.fr
Site Name
Centre Hospitalier Groupe Hospitalier Rance Emeraude
Department Name
Nephrology
Principal Investigator Name
Eric RENAUDINEAU
Principal Investigator Email
e.renaudineau@ch-stmalo.fr
Contact Person Name
Eric RENAUDINEAU
Contact Person Email
e.renaudineau@ch-stmalo.fr
Site Name
Clinique Nephrologique Saint Exupery
Department Name
Nephrology
Principal Investigator Name
Antoine DELARCHE
Contact Person Name
Antoine DELARCHE
Site Name
Hopital NOVO
Department Name
Nephrology
Principal Investigator Name
Charlotte JOUZEL
Principal Investigator Email
charlotte.jouzel@ght-novo.fr
Contact Person Name
Charlotte JOUZEL
Contact Person Email
charlotte.jouzel@ght-novo.fr
Site Name
Centre Hospitalier Universitaire De Poitiers
Department Name
Nephrology
Principal Investigator Name
Frank BRIDOUX
Principal Investigator Email
f.bridoux@chu-poitiers.fr
Contact Person Name
Frank BRIDOUX
Contact Person Email
f.bridoux@chu-poitiers.fr
Site Name
Centre Hospitalier De Boulogne Sur Mer
Department Name
Nephrology
Principal Investigator Name
Rafik MESBAH
Principal Investigator Email
r.mesbah@ch-boulogne.fr
Contact Person Name
Rafik MESBAH
Contact Person Email
r.mesbah@ch-boulogne.fr
Site Name
Centre hospitalier de Saint-Nazaire
Department Name
Nephrology
Principal Investigator Name
Domnique BESNIER
Principal Investigator Email
d.besnier@ch-saintnazaire.fr
Contact Person Name
Domnique BESNIER
Contact Person Email
d.besnier@ch-saintnazaire.fr
Site Name
Les Hopitaux Universitaires De Strasbourg
Department Name
Nephrology
Principal Investigator Name
Eric PRINZ
Principal Investigator Email
eric.prinz@chru-strasbourg.fr
Contact Person Name
Eric PRINZ
Contact Person Email
eric.prinz@chru-strasbourg.fr
Site Name
Centre Hospitalier Bretagne Atlantique
Department Name
Nephrology
Principal Investigator Name
Hugoline BOULAY
Principal Investigator Email
hugoline.boulay@ch-bretagne-atlantique.fr
Contact Person Name
Hugoline BOULAY
Site Name
Centre Hospitalier Intercommunal De Mont De Marsan Et Du Pays Des Sources
Department Name
Nephrology
Principal Investigator Name
Magail JASIEK
Principal Investigator Email
magali.jasiek@ch-mdm.fr
Contact Person Name
Magail JASIEK
Contact Person Email
magali.jasiek@ch-mdm.fr
Site Name
Centre Hospitalier D Avignon
Department Name
Nephrology
Principal Investigator Name
David VERHELST
Principal Investigator Email
dverhelst@ch-avignon.fr
Contact Person Name
David VERHELST
Contact Person Email
dverhelst@ch-avignon.fr
Site Name
Centre Hospitalier Alpes-Leman
Department Name
Nephrology
Principal Investigator Name
Martin JANNOT
Principal Investigator Email
jannotmartin@gmail.com
Contact Person Name
Martin JANNOT
Contact Person Email
jannotmartin@gmail.com
Site Name
Expansion des Centres d'Hemodialyse de l'Ouest
Department Name
Nephrology
Principal Investigator Name
Guillaume SERET
Principal Investigator Email
gseret@echo-sante.com
Contact Person Name
Guillaume SERET
Contact Person Email
gseret@echo-sante.com
Site Name
Centre Hospitalier Yves Le Foll
Department Name
Nephrology
Principal Investigator Name
Caroline FREGUIN
Principal Investigator Email
caroline.freguin@ch-stbrieuc.fr
Contact Person Name
Caroline FREGUIN
Site Name
University Hospital Of Clermont-Ferrand
Department Name
Nephrology
Principal Investigator Name
Julien ANIORT
Principal Investigator Email
janiort@chu-clermontferrand.fr
Contact Person Name
Julien ANIORT
Contact Person Email
janiort@chu-clermontferrand.fr
Site Name
Centre Hospitalier Regional De Marseille
Department Name
Nephrology
Principal Investigator Name
Noémie JOURDE
Principal Investigator Email
noemie.jourde@ap-hm.fr
Contact Person Name
Noémie JOURDE
Contact Person Email
noemie.jourde@ap-hm.fr
Site Name
Bicetre Hospital
Department Name
Nephrology
Principal Investigator Name
Antoine DURRBACH
Principal Investigator Email
antoine.durrbach@bct.aphp.fr
Contact Person Name
Antoine DURRBACH
Contact Person Email
antoine.durrbach@bct.aphp.fr
Site Name
Centre Hospitalier De Valenciennes
Department Name
Nephrology
Principal Investigator Name
Claire CARTERY
Principal Investigator Email
cartery-c@ch-valenciennes.fr
Contact Person Name
Claire CARTERY
Contact Person Email
cartery-c@ch-valenciennes.fr
Site Name
Hopital Henri Mondor - 1 rue Gustave Eiffel
Department Name
Nephrology
Principal Investigator Name
Nizar JOHER
Principal Investigator Email
nizar.joher@aphp.fr
Contact Person Name
Nizar JOHER
Contact Person Email
nizar.joher@aphp.fr
Site Name
Centre Hospitalier Universitaire De Bordeaux
Department Name
Nephrology
Principal Investigator Name
Christian COMBE
Principal Investigator Email
christian.combe@chu-bordeaux.fr
Contact Person Name
Christian COMBE
Site Name
Centre Hospitalier Universitaire De Nice
Department Name
Nephrology
Principal Investigator Name
Marine ANDREANI
Principal Investigator Email
andreani.m@chu-nice.fr
Contact Person Name
Marine ANDREANI
Contact Person Email
andreani.m@chu-nice.fr

Sponsor

Primary sponsor

Full Name
Centre Hospitalier Departemental Vendee
Organisation Type
Hospital/Clinic/Other health care facility
Country Of Registered Address
France

Investigational products

Investigational Product Name
RITUXIMAB
Active Substance
RITUXIMAB
Modality
Monoclonal antibody
Routes Of Administration
INJECTABLE SOLUTION
Route
INJECTABLE SOLUTION
Authorisation Status
Authorised
Maximum Dose
500 mg
Investigational Product Name
AZATHIOPRINE
Active Substance
AZATHIOPRINE
Modality
Small molecule
Routes Of Administration
ORAL
Route
ORAL
Authorisation Status
Authorised
Maximum Dose
2 mg/kg
Investigational Product Name
PREDNISONE (CORTANCYL 20 mg)
Active Substance
PREDNISONE / PREDNISOLONE
Modality
Small molecule
Routes Of Administration
ORAL
Route
ORAL
Authorisation Status
Authorised
Maximum Dose
20 mg
Investigational Product Name
MYCOPHENOLATE MOFETIL (Mycophenolate mofetil Tillomed 500 mg)
Active Substance
MYCOPHENOLATE MOFETIL
Modality
Small molecule
Routes Of Administration
ORAL
Route
ORAL
Authorisation Status
Authorised
Maximum Dose
2 g
Combination Treatment
Yes

Related trials

Other published trials that may interest you.